Actelion Pharmaceuticals Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Actelion Pharmaceuticals Ltd.
ITM is reaping benefits from long-term investment in radiopharmaceuticals manufacturing and is now looking to challenge its customer, Novartis, by bringing its first product to market.
Evobrutinib flunked its Phase III multiple sclerosis program not because of its known toxicity, but because it didn’t work.
Environmental demands, the evolution of care models, new delivery technologies and AI tools are influencing how medtechs must approach innovation.
New markets, a patent cliff, an M&A rebound and clinical trial catalysts. How will it all play out for the biopharma sector in 2024?
- Other Names / Subsidiaries
- Ceptaris Therapeutics, Inc. (Yaupon Therapeutics, Inc.)
- CoTherix, Inc
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.